[go: up one dir, main page]

WO2024075123A1 - Procédé électrochimique de détection du cancer - Google Patents

Procédé électrochimique de détection du cancer Download PDF

Info

Publication number
WO2024075123A1
WO2024075123A1 PCT/IL2023/051060 IL2023051060W WO2024075123A1 WO 2024075123 A1 WO2024075123 A1 WO 2024075123A1 IL 2023051060 W IL2023051060 W IL 2023051060W WO 2024075123 A1 WO2024075123 A1 WO 2024075123A1
Authority
WO
WIPO (PCT)
Prior art keywords
electrode
electrodes
coated
electrochemical
array
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2023/051060
Other languages
English (en)
Inventor
Hadar Shmuel BEN-YOAV
Avia LAVON
Anat Tzipora TZUR
Gal Markel
Assaf BAR EL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sheba Impact Ltd
BG Negev Technologies and Applications Ltd
Original Assignee
Sheba Impact Ltd
BG Negev Technologies and Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sheba Impact Ltd, BG Negev Technologies and Applications Ltd filed Critical Sheba Impact Ltd
Priority to EP23874441.1A priority Critical patent/EP4599240A1/fr
Publication of WO2024075123A1 publication Critical patent/WO2024075123A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28—Electrolytic cell components
    • G01N27/30—Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
    • G01N27/3277—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a redox reaction, e.g. detection by cyclic voltammetry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Definitions

  • Non-invasive methods based on the testing of biofluids to determine, for a cancer patient or a subject suspected of having cancer, which is the organ of cancer involvement, are of great importance. For example, detection of urologic cancer by the testing of urine sample.
  • the major types of urologic cancers include prostate cancer (PC) and bladder cancer (BC) , which are the second and fourth most common cancer in men, respectively.
  • PC prostate cancer
  • BC bladder cancer
  • urine-based screening of urologic cancers that is, by testing urine sample taken from a patient for the presence of a biomarker or a fingerprint associated with the organ of cancer involvement, e.g., the urine bladder or prostate.
  • Electrochemistry could be incorporated into urinalysis, to serve the purpose of cancer detection. Integration of electrochemical tools into the diagnosis of cancer is based on the inherent redox nature of most of the metabolites involved.
  • An electrochemical approach offers reduced diagnostic time and potential miniaturization - an important consideration because a biofluid sample taken from a patient often has limited volume. Consequently, an electrochemical measurement cell should be designed to accommodate and test a small volume of the biofluid sample.
  • alpha-methylacyl-CoA racemase an enzyme that is overexpressed in prostate cancer epithelium and hence can serve as a potential biomarker for cancer cells within the prostate gland, can be quantified voltammterically using a biosensor consisting of a three-electrode configuration (counter electrode, reference electrode and one working electrode that was made of iridium oxide and active carbon powder) .
  • the current at the working electrode is measured as the potential applied across the working electrode and the counter electrode is varied with time.
  • electroactive species When electroactive species are present in the tested sample, they undergo oxidation (or reduction) when the potential on the working electrode is sufficiently positive (or negative) .
  • the oxidation/reduction electrochemical reactions are manifested by an increase in the current (anodic or cathodic) measured; that is, creation of an electrochemical signal with magnitude and position characteristic of a given analyte.
  • a "voltammetric electronic tongue" a device employing an array consisting of a few working electrodes that are different from another, i.e., the working electrodes are made of different metals or are surface-modified in a different manner (coated with distinct types of films) , as described, for example, by del Valle, M. Electronic tongues employing electrochemical sensors. Electroanalysis vol. 22 1539- 1555 (2010) . Thus, the sensor array has semi-selective electrodes and cross-response features to "sense" more information.
  • Voltammetric electronic tongues have also been suggested for use in connection with measurements in biofluids [Saidi et al. Voltammetric electronic tongue combined with chemometric techniques for direct identification of creatinine level in human urine. Meas. J. Int. Meas. Confed. 115, 178-184 (2016) ; Pascual, L. et al. Detection of prostate cancer using a voltammetric electronic tongue.
  • an electrochemical signal measured in a urine sample can serve as a holistic electrochemical marker to detect types of cancer whose " fingerprint" can be found in the urine , e . g . , urologic cancer, to distinguish BC or PC patients not only from other cancer patients but also from patients with inflammation .
  • the electrochemical signal was generated by the total of redox-active species present in the urine sample , namely antioxidants and oxidants and was recorded with the aid of voltametric electronic tongue .
  • the working electrodes incorporated into the device include a combination of bare electrode ( s ) and surface-modi fied electrode ( s ) , which were selected based on their partial selectivity and cross-reactivity towards the antioxidant and oxidant systems . That is , the electrodes sense the cumulative ef fect of all antioxidants and oxidants present in the urine sample .
  • ascorbic acid was used as a marker of Total Antioxidant Capacity ( TAG ) and hydrogen peroxide was used as a marker of Total Oxidant Status ( TOS ) , and the electrodes were tested with respect to their ability to quanti fy these two markers .
  • the invention is primarily directed to a method of screening and/or monitoring a patient for cancer that is detectable in urine , comprising : obtaining a urine sample from the patient ; acquiring an electrochemical signal generated jointly by redox molecules in the urine sample, wherein the signal is acquired with the aid of an array of surface-modified electrodes that is sensitive for antioxidant and oxidant, wherein the array optionally further comprises one or more bare electrodes; optionally preprocessing the electrochemical signal, to obtain processed data; applying trained chemometric model (s) to the processed or raw data; and determining the presence of cancer in the patient and/or monitorable cancer-related features (such as recurrence and/or progression of the disease, effectiveness of treatment, tumor classification) , after the chemometric model has classified the processed data according to its training data set.
  • a urine sample from the patient ; acquiring an electrochemical signal generated jointly by redox molecules in the urine sample, wherein the signal is acquired with the aid of an array of surface-modified electrodes that is sensitive for
  • the preferred electrochemical technique to record the fingerprint of BC/PC in urine samples is voltammetry (application of varied voltage and measurement of current) , such as differential pulse voltammetry (DPV) .
  • voltammetry application of varied voltage and measurement of current
  • DUV differential pulse voltammetry
  • the description that follows focuses on in vitro detection of urologic cancer by the testing of urine sample, but other types of cancer, e.g., lung cancer and colorectal cancer, which have been shown to be detectable in urine, are included within the scope of the invention. See Mallaf re-Muro, C. et al. [Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis . Cancers
  • Figure 1 shows the major components of the approach to urinary detection of BC or PC patients, namely, a urine sample that was taken from the patient and an array of electrodes to be inserted into the sample.
  • the electrodes are connected to a potentiostat (which vary the potential across the electrodes to record a voltammogram) .
  • the voltammogram (or any other electrochemical signal) is resolved by the chemometric model to classify the urine sample as belonging to a specific type of urologic cancer.
  • the array of working electrodes is an assembly of a few sets of electrodes, each set consisting of electrode (s) of the same type.
  • electrodes of the same type we mean either bare electrode that are made of the same material (e.g., of the same noble metal) , or electrodes coated with the same film material.
  • the number of electrodes of type i is marked n ⁇ .
  • five types (sets) of working electrodes are listed below (from which at least two sets, or at least three sets, can be chosen to create an array for voltammetry measurements in urine samples) :
  • bare electrodes are preferably made of noble metals, e.g., gold, platinum, rhodium, and iridium. Also, other electrodes, such as carbon electrodes, can be incorporated into the array of working electrodes. Gold is generally preferred, both for use as bare electrodes and surface-modified electrodes.
  • polysaccharide e.g., chitosan
  • a set consisting of electrodes coated with polysaccharide (e.g., chitosan) film with conductive additives incorporated into the film, such as carbon nanotubes; typical film thickness is from 1 to 100 pm, e.g., 5 to 60 pm.
  • polysaccharide e.g., chitosan
  • a set consisting of electrodes coated with reduced graphene oxide film typically thickness is 200 to 1,000 nm, e.g., 350 to 550 nm.
  • a set consisting of electrodes coated with platinum black film typically film thickness is from 1 to 50 pm, e . g . , 6 to 10 pm .
  • n ⁇ - the number of electrodes in each set - is usually up to 3 .
  • an ef ficient array design calls for a small number of working electrodes which could easily fit into a suitable electrochemical measurement cell , i . e . , by selecting less than five types of electrodes and reducing the number of electrodes of each type ( set ) .
  • the experimental results shown below indicate that good results are obtained with a combination of three sets of electrodes consisting of bare ( e . g .
  • the electrochemical detection of BC/PC in urine samples is not limited to the use of electrodes coated with platinum black, reduced graphene oxide , chitosan, and CNT-added chitosan .
  • the experimental work reported below shows how to apply suitable selection criteria so as to create an ef fective array with a fairly small number of bare and coated electrodes , based on the assumption that electrodes with good sensitivity towards ascorbic acid and hydrogen peroxide would accurately sense the total ef fect of all antioxidants and oxidants present in the urine sample, which in turn account for the existence of an electrochemical fingerprint of BC/PC cancer in urine samples .
  • the electrochemical performance of coated electrodes can be examined by cyclic voltammetry in ferrocyanide/ ferricyanide redox couple solution - a benchmark frequently used to assess the acceptability of surface-modi fied electrodes .
  • cyclic voltammetry can be used to assess the detectability of AA and H2O2 by each of the candidate working electrodes in G, by measuring the concentrations of AA and H2O2 ( each separately) in PBS , across applicable concentration ranges , say, from 0 . 1 to 10 mM, to show linearity of current peak versus concentration curves .
  • the slope of the linear equation fitted to the curve indicates the sensitivity of the tested electrode i towards the analyte (AA or H2O2 ) , and is designated Working electrodes (bare or surface modi fied) , with sensitivity above 3 . 0 mA/M, either towards AA or are generally preferred for use in the sensor .
  • Partial selectivity is yet another useful selection criterion .
  • Partial selectivity ( PS ) is calculated by dividing the sensitivity of electrode i towards ascorbic acid by the sensitivity of the same electrode towards H2O2 . The ratio obtained is ( or its inverse ,
  • the array used for the electrochemical detection of urologic cancer in a patient comprises at least one working electrode showing partial selectivity for ascorbic acid/hydrogen peroxide of above 5 (that is , and at least one working electrode showing partial selectivity for hydrogen peroxide/ascorbic acid of above 2 (that is, .
  • bare gold electrode and platinum black coated electrode show above 2, respectively, and are therefore especially preferred for use in the invention.
  • the platinum black-coated electrode seems to be quite unique in that it demonstrates increased partial selectivity towards hydrogen peroxide compared to the other electrodes .
  • Cross reactivity can then be calculated over a combination I consisting of, say, three different types of electrodes where i and k are two different types of electrodes in the combination I and j the target analytes.
  • a combination I can then be rejected or accepted based on its CR.
  • Il ⁇ bare electrode, Pt coated electrode, chitosan +CNT coated electrode ⁇ ;
  • a sensor based on the II combination (bare, Pt coated and chitosan +CNT coated electrodes) and a device comprising the sensor, a counter electrode and optionally a reference electrode; a potentiostat/ galvanostat, and a processor configured to analyze the electrochemical signal by one or more chemometric techniques, form additional separate aspect of the invention.
  • the coatings mentioned above (made of platinum black, reduced graphene oxide, chitosan, and chitosan to which conductive additive was added, such as carbon nanotubes) are applied onto surfaces of bare electrodes (e.g., on a 1 to 5 mm diameter disc shape commercial gold electrode) by a suitable electrodeposition technique :
  • Platinum black film can be generated via galvanostatic electrodeposition onto one or more electrodes, by passing a constant current (a cathodic current, with current density fixed in the range of 0.1 to 4 mA/ cm 2 , for 3 to 7 minutes; for example, a current density of 0.3 mA/ cm 2 is supplied over five minutes) , through a deposition solution in which a suitable platinum source is dissolved, e.g., by electrochemical reduction of chloroplatinic acid dissolved in DI water at a concentration in the range of 1% (w/w in water) to 3% (w/w in water) , in the presence of about 0.05% (w/w in water) of lead acetate.
  • a constant current a cathodic current, with current density fixed in the range of 0.1 to 4 mA/ cm 2 , for 3 to 7 minutes; for example, a current density of 0.3 mA/ cm 2 is supplied over five minutes
  • a deposition solution in which a suitable platinum source is dissolved, e
  • Lead acetate enhances the electrode reaction (i.e., the reduction of Pt) in presence of platinum black solution and it also strengthens the adhesion of the coating to the electrode.
  • the pH of the deposition solution is shifted to the strongly acidic by addition of hydrochloric acid.
  • a two-electrode configuration can be used, which includes the electrodes to be coated as working electrode (s) and a ring or wire Pt counter electrode.
  • Another type of film-forming material that is applied to create film-coated microelectrode ( s ) is reduced graphene oxide.
  • the deposition solution is prepared by known methods, e.g., the Hummers' method, where oxidation of graphite flakes or powder takes place upon adding the graphite to a cold solution of sulfuric acid (e.g., 0°C) followed by gradual addition of sodium nitrate and potassium permanganate under continuous stirring.
  • a cold solution of sulfuric acid e.g., 0°C
  • sodium nitrate and potassium permanganate e.g., sodium nitrate and potassium permanganate under continuous stirring.
  • the addition time of each of the successively added NaNOs and KMNO4 reagents is not less than ten to fifteen minutes.
  • the reaction mixture is heated to about 35-45°C and kept under stirring for a couple of hours, e.g., not less than two hours.
  • the reaction is terminated by addition of water and hydrogen peroxide which removes excess permanganate.
  • the graphene oxide (GO) is recovered by centrifugation and freeze dried and used to prepare deposition solution with concentrations in the range from 0.1 to 0.9 mg/ml GO.
  • a deposition solution can also be prepared by a modified Hammers procedure, which consists of adding the graphite powder (or flakes) to a mixed sulfuric acid/phosphoric acid solution (e.g., proportioned about 9:1 by volume) , followed by the slow addition of KMnO4. The mixture is kept under stirring for couple of hours at a slightly elevated temperature (at 30-35 °C) until the mixture acquires a dark green color. Termination of the reaction is achieved by slow addition of H2O2 aqueous solution (e.g., the commercial 30% w/w solution) .
  • H2O2 aqueous solution e.g., the commercial 30% w/w solution
  • Graphene oxide is recovered through acidification of the mixture by hydrochloric acid (e.g., addition of commercial 32% HC1 solution and DI) , centrifugation of the resulting solution, washing of the supernatant with HCl/water, drying of the washed solution (e.g., at 90 °C in an oven) and collecting the GO powder.
  • the dried GO powder is dissolved in DI, usually up to concentration of 0.5 g/L GO concentration. Addition of an electrolyte to the GO solution affords the GO electrodeposition solution.
  • r-GO is obtained electrochemically from the GO solution onto the electrode (Au) surface, using cyclic voltammetry electrodeposition, in a three- electrode cell configuration consisting of the Au electrode (s) as working electrode ( s ) ; an externally applied Pt wire as counter electrode and Ag/AgCl as reference electrode.
  • a potential window for example from -1.4. to 1.4V (versus Ag/AgCl) is scanned at rate of in the range of to 50 to 500 mV/s, with number of cycles varying from 1 to 5.
  • Electrodeposited chitosan film-coated electrode can be prepared with the aid of a deposition solution with chitosan concentration in the range from 0.5 to 2.0 wt%, preferably from 0.8 to 1.2 wt%, prepared by dissolving chitosan in a strongly acidic environment, whereby the amino groups undergo protonation to reach a slightly acidic pH (5-6) .
  • a deposition solution with chitosan concentration in the range from 0.5 to 2.0 wt%, preferably from 0.8 to 1.2 wt% prepared by dissolving chitosan in a strongly acidic environment, whereby the amino groups undergo protonation to reach a slightly acidic pH (5-6) .
  • conductive additives can be included in the deposition solution; these additives will co- deposit and affect the film properties.
  • the concentration of the additives in the deposition solution is in the range from 0.1 to 2 %, preferably from 0.8 to 1.8 wt . % .
  • chitosan-CNT electrodeposition solution can be prepared by mixing a chitosan solution as previously described with CNTs, followed by ultra-sonication.
  • the electrode is immersed in the chitosan deposition solution (or chitosan/CNT solution) and electrodeposition is achieved by the chronopotentiometry technique, i.e., selected electrodes to be coated are biased to the negative potential against a counter electrode with constant (cathodic) current being applied between the electrodes for a period of time of 0.5 to 5 min, supplied by a DC current source; typically the current is set in the range from 3 to 6 ⁇ A/ cm 2 .
  • a two-electrode configuration can be used, i.e., the counter electrode is shorted to reference terminal. Weakly bound chitosan is removed from the microelectrode surface, by immersing the device in a buffer solution.
  • the electrochemical sensor could benefit from the incorporation of other types of surface-modified working electrodes, e.g., those described in WO 2022/137236, where coatings consisting of transition metal dichalcogenide (TMDC) of the formula MX2, in which M is a transition metal (such as molybdenum and tungsten) and X is S or Se, are described.
  • TMDC transition metal dichalcogenide
  • TMDC A and TMDC B for example, MoS2 A and MoS2 B , it is meant TMDC coatings electrodeposited on an electrode surface by the following methods :
  • TMDC A cycling a potential range A, which corresponds to the electrochemical double layer (EDL) potential region of the working electrode, at a scanning rate of at least 0.05 V-s -1 , e.g., from 1.0 to 10.0 V-s -1 ;
  • TMDC B cycling a potential range B, which extends to more positive potentials than potential range A (extended EDL) at a scanning rate of at least 0.05 V-s -1 , e.g., from 0.05 to 2.0 V-s -1 .
  • potential range A is above -0.4 V, e.g., from -0.3 to +0.7 V (vs Ag/AgCl) and potential range B is above -0.4 V and extends up to +1.3 V or up to +1.4 V (vs Ag/AgCl) , e.g., from 0 to +1.4 V (vs Ag/AgCl) .
  • potential range B is above -0.4 V and extends up to +1.3 V or up to +1.4 V (vs Ag/AgCl) , e.g., from 0 to +1.4 V (vs Ag/AgCl) .
  • the same potential ranges A and B can be used.
  • TMDC A -coated electrodes When the electrodes are made of gold, one way to differentiate between TMDC A -coated electrodes and TMDC B -coated electrodes is that the latter type shows the presence of hydroxide or oxide species associated with the metal electrode, e.g., for gold electrode, concomitant formation of a gold hydroxide adduct and the formation of a gold oxide layer occur (at +0.8 V vs Ag/AgCl and at +1.3 V vs Ag/AgCl in the extended EDL region, respectively) , as determined, for example, by Raman spectroscopy or X-ray photon spectroscopy.
  • TMDC A -coated electrodes shows lower capacitive currents (e.g., at least two-fold lower) and higher charge transfer resistance (e.g., at least ten fold-higher) than the latter type, as measured by electrochemical impedance spectroscopy (EIS) acquired by a solution of the ferrocyanide/ ferricyanide redox couple by the technique described in detail in WO 2022/137236.
  • EIS electrochemical impedance spectroscopy
  • the sensor used in the present invention may include one or more MoS2 A -coated electrodes, and/or one or more MoS2 B -coated electrodes, and/or one or more WS2 A -coated electrodes, and or one or more WS2 B -coated electrodes, which were prepared by electrodeposition onto the surfaces of the working electrodes across potential ranges A and B, respectively, wherein potential range A corresponds to the double layer potential region of the working electrode and potential range B extends to more positive potentials than potential range A; such that, for example, for working electrodes made of noble metals, type B shows the presence of hydroxide form(s) and/or high oxidation state oxide forms (s) of the noble metal, whereas working electrodes of type A are free of such forms; and/or working electrodes of type B show higher capacitive currents and lower charge transfer resistance compared to working electrodes of subset A, as determined by electrochemical impedance spectroscopy.
  • WO 2022/137236 describes the preparation of electrodeposition solutions and
  • the array of working electrodes used in the method of the invention comprises at least two sets of electrodes (e.g., 2- 5 sets, or 6-8 sets, or 6-9 sets) selected from:
  • the arrays of working electrodes for example: (a total of ten electrodes ) ; (a total of eight electrodes) . may be arranged in different designs and geometries.
  • one simple and straightforward configuration is based on the use of an electrochemical measurement cup to hold the urine sample (e.g., not less than 3 ml sample) , fitted with a perforated cover ; the holes in the cover correspond in number and si ze to the electrodes , such that individual working electrodes can be inserted into the measurement cup through the holes to be immersed in the sample .
  • Commercial counter electrode e . g . , commercial Pt wire
  • commercial reference electrode Ag/AgCl
  • a more sophisticated design is the one shown in WO 2018 /225058 . It was based on a cylindrical body made of silicon, polyvinyl alcohol or polydimethylsiloxane , which was 2 to 5 cm long and with diameter is in the range from 2 to 3 cm .
  • the accessible surfaces of the electrodes were deployed on one base of the tubular body : a discshaped reference electrode positioned concentrically and coaxially in respect to the cylindrical body, a counter electrode at the vicinity of the reference electrode and multiple surface modi fied working electrodes ( 3 . 14 mm 2 each) positioned in radial direction from the reference and counter electrodes and evenly distributed along the perimeter of the base of the cylindrical body .
  • the opposite base provides the electrical wiring to be connected to potentiostat/galvanostat (the electrodes extend along the cylindrical body and are connected to the wiring in the opposite base ) .
  • the electrochemical sensor is immersed in the urine sample to be analyzed such that the base of the cylinder, where the electrodes are disposed, is exposed to the sample allowing the electrodes that ( optionally) protrude from the base to be dipped into the urine sample , creating the electrochemical cell for the measurements .
  • FIG. 11 An electrochemical sensor in the form of a microfabricated 1 . 5cm x 1 . 5cm chip ( 1 ) on a glass substrate is shown. It can be a portable device or can be placed in the lab. The device dimensions are compatible with the conventional microfabrication techniques where the diameter of the working microelectrodes (4) is ⁇ 100 micrometer and the diameter of counter electrode (3) is ⁇ 500 micrometer.
  • the chamber (5) is designed to hold small volume samples (10-30 microliter) .
  • Reference electrode (2) can be integrated into the array by electroplating one or two microelectrodes with Ag/AgCl as previously described (see Example 6 of WO 2022/137236) .
  • the chambers are made of insulating polymer, e.g., SU-8 polymer (6) .
  • the contacts pads (7) can be connected via pogo pins (8) and then to the multichannel connection (9) of the potentiostat or galvanostat unit (10 not shown) .
  • the device may be powered by a battery or alternatively, can be connected to a main power supply.
  • a control unit (not shown) is designed to serve several purposes, chiefly controlling the potential of the working electrodes or the current flowing through the cell, respectively, according to the chosen electrochemical technique.
  • the microsensor described above (which consists of microelectrodes, microchambers encompassing the microelectrodes, all confined within a recessed zone that serves as a receptable for holding the liquid sample) can be created over a substrate by techniques such as etching and photolithography. Briefly, a substrate is cleaned, a first photoresist is applied (either negative, positive or image reversal resist) , e.g., by spin coating, spray coating or dip coating, to produce a thin uniform layer on the substrate, followed by soft baking. A first mask is aligned, to transfer the pattern corresponding to electrodes' sites onto the surface of the substrate. The photoresist is exposed through the pattern on the mask with UV light, followed by a development step.
  • a first photoresist is applied (either negative, positive or image reversal resist) , e.g., by spin coating, spray coating or dip coating, to produce a thin uniform layer on the substrate, followed by soft baking.
  • a first mask
  • bare microelectrodes are deposited in the intended sites, e.g., first titanium which serves as an adhesion layer and then gold followed by lift off procedure that resulted in a gold microelectrode array on glass substrate.
  • another lithography step was done using, e.g., SU-8 photoresist.
  • another photolithography step was followed with e.g., thick SU-8 resist.
  • the desired coatings are applied on the gold microelectrodes, for example, by electrodeposition.
  • the fabrication of such microsensors by photolithography and etching, followed by surface modification by electrodeposition, is described in detail in WO 2022/137236 (see Figures 9A, 9B, 9C and 10 and Example 6 of WO 2022/137236) .
  • the counter electrode (labeled “AUX” for auxiliary) is ringshaped, e.g., Pt ring with inner and outer diameters of 15 to 20 mm (e.g., 18mm) and 21 to 25 (e.g., 22 mm) , respectively.
  • the reference electrode (labeled "REF”, e.g., Ag/AgCl coated electrode as previously described) , is centrically positioned; it's surface area is about 30 to 40 mm 2 e.g., e.g., 36mm 2 .
  • the working electrodes are placed in the annular space between the counter (outer) and reference (inner) electrodes, e.g., equally spaced apart from one another, and at distance of 4 to 8 mm, e.g., 6 mm from the center of the reference electrode.
  • Each working electrode is disc-shaped with surface area of 25-30 mm 2 , e.g., 27mm 2 .
  • Figure 13A In the specific configuration of Figure 13A, the following combination of working electrodes was assembled: a bare (gold or carbon) electrode, a chitosan/CNT-coated gold/carbon electrode, a platinum black-coated gold/carbon electrode, a reduced graphene oxidecoated gold/carbon electrode, a MoS2 A -coated gold/carbon electrode, a MoS2 B -coated gold/carbon electrode, WS2 A -coated gold/carbon electrode and WS2 B -coated gold/carbon electrode.
  • Figure 13B is a photograph showing a small plastic housing (20 ) for the ring-shaped array of electrodes of Figure 13A.
  • the electrodes can be coated as previously explained and the surface-modi fied array is encased in the plastic housing (20 ) , which is provided with a central circular opening (21 ) at its top .
  • a urine sample container (22 ) can be fitted to the opening, to discharge the liquid sample onto the electrodes .
  • the electrical connectors (23 ) extending from the bottom of the plastic housing are also shown .
  • the electrodes are electrically connected to potentiostat or galvanostat which control the potential or current of the working electrodes , respectively, to create a data set of electrochemical signals when the electrodes are in contact with the test urine sample (the sample may be pretreated, i . e . , steps such as freezing and thawing or centri fuging) .
  • the data set of electrochemical signals is analyzed by a processor applying one or more chemometric techniques .
  • Figures 11- 12 provide a schematic illustration of the electrochemical sensor according to the invention and a detection device into which the sensor is incorporated, i . e . , either a portable device or a fixed device placed in a lab etc .
  • the device may further include a data storage unit or a data transmitting unit , i . e . , wired transmitter or a wireless network transmitting unit with conventional communication ports to deliver the data to an externally located data storage unit .
  • a data storage unit may be the memory of the data processing unit or any computer readable media.
  • personal instruments are shown and also a cloud-based data storage system.
  • the device further comprises a processor for analyzing a data set of electrochemical signals by one or more chemometric techniques, e.g., multivariate methods such as a supervised machine learning model (artificial neural network (ANN) ) , or a regression model, e.g. partial least square regression (PLSR) .
  • chemometric techniques e.g., multivariate methods such as a supervised machine learning model (artificial neural network (ANN) ) , or a regression model, e.g. partial least square regression (PLSR) .
  • ANN artificial neural network
  • PLSR partial least square regression
  • PLSR is a linear regression method and PLSR algorithms are available (e.g., MATLAB) .
  • ANN a neural network model is generated with the aid of a training set. To this end, a matrix consisting of large number of samples with known concentrations of the analyte and with known outputs is collected. As explained in more detail below, the data set is split to create a training set, a cross-validation set and a test set. In the training process, the error between the outputs predicted by the neural network and the known outputs is calculated; this process continues, with the algorithm adjusting the parameters iteratively to minimize the error, i.e., to reduce the error below an acceptable level. Once created, the model is saved and can be used for future measurements of test samples.
  • raw test data collected by the electrochemical sensor undergoes pre-processing with the aid of known techniques before it is fed to the algorithm.
  • methods such as principal component analysis (PCA) , Fast Fourier Transform (FFT) , and selection of important electrochemical signal features, can be used to reduce the dimensions of the data fed to the model.
  • PCA principal component analysis
  • FFT Fast Fourier Transform
  • the latter method has been shown to be especially useful; the features selected (e.g., from the voltammograms ) include peak current, peak potential, maximum slopes of the I vs . E function (for the increasing and decreasing parts of the function) .
  • the sample is placed in the sample holder in contact with the electrochemical sensor in the device of the invention, as described above, varied voltage is applied by the potentiostat between the reference electrode and working electrodes, currents generated are measured and the measurements are stored, and the test data collected (readings from all working electrodes) is preprocessed, reduced and scaled, fed to the algorithm to obtain the model input.
  • Signal smoothing - by using the signal processing toolbox, MATLAB software 2017a version, a built-in function (e.g. 'filter' ) can be used to filter the signals by employing a moving average window in order to reduce signal fluctuations and noisy behavior which is not originated by the electrochemical properties of the tested solution.
  • a varied filter order in the range of 5 ⁇ M ⁇ 8, (M - filter order) can be used. In order to keep this parameter as unbiased for all the recorded signals in each experiment, it is kept fixed and equal to specific value for each experimental data.
  • each electrode's signal is normalized by its electrode's effective surface area (A e ff) .
  • the electrode's effective surface area is obtained by experimental cyclic voltammetry with ferrocyanide and ferricyanide solution.
  • the data is separated into two or three distinct sets.
  • the first set is a training set, that is used for the training and the design of the model. All optimization procedures for finding the optimal solution are performed on the training set. It should be noted that the training set could be sub-divided to create a small cross- validation set.
  • the other set is the test set. This set is used to check the model's generalization capabilities, by using the trained model in order to evaluate ability of the model to predict the concentrations in the "unseen" samples.
  • the data is usually divided as follows: 70-85 % of the samples are assigned to the training set (including ⁇ 10% that may be used for cross-validation) and 10-30% for testing. The samples are divided randomly, but the computer's random generation is fixed to assure that the same subdivision could be reproduced.
  • the CV method (LOOCV and 10-fold CV) was used.
  • the CV was implemented in the MATLAB software 2017a version, using the ' cvpartition ' function from the statistical toolbox, for random divisions into k sets. By dividing the train set and using it also for validation we were able to take advantage of most of the information hidden in the data. Model parameters minimizing the cross-validation error were chosen .
  • Model training- the best number of latent variables and best electrode combinations were chosen for training the model on all the training set.
  • Test Data pre-processing - the test signals were centered according to the mean average value of the training set.
  • Model predictability the trained model was used to test and evaluate the performance on unseen data set, i.e., the test set, which was preprocessed and was ready for use as the model input.
  • Ccaicuiated is the predicted value) .
  • Feature extraction - specific electrochemical signal features were extracted, i.e., features which are indicative of the identity of the redox-active molecule and its concentration in the solution.
  • the extracted features include: peak potential, peak current, maximum slope of the signal, and current value at specific potentials (potentials which are known as the standard oxidationreduction potential of specific analyte - good evaluation when the peak is not visible) . All features extracted automatically using MATLAB software 2017a version built-in functions and by customary- built specific functions for each feature.
  • the data is separated into two or three distinct sets.
  • the first set is a training set, that is used for the training and the design of the model. All optimization procedures for finding the optimal solution are performed on the training set. It should be noted that the training set could be sub-divided to create a small cross- validation set, as explained below and further illustrated in the Examples below.
  • the other set is the test set. This set is used to check the model's generalization capabilities, by using the trained model in order to evaluate ability of the model to predict the concentrations in the "unseen” samples.
  • the data is usually divided as follows: 70-85 % of the samples are assigned to the training set (including ⁇ 10% that may be used for cross-validation) and 10-30% for testing. The samples are divided randomly, but the computer's random generation is fixed to assure that the same subdivision could be reproduced. 6 .
  • Feature normali zation - features were standardi zed using the z- score trans formation ( subtracting the mean value of each feature , and scaling it by dividing the value by the standard deviation) . Scaling was preformed because the features were in di f ferent scales , such as peak currents and peak potentials [V] .
  • the data trans formation was achieved with the aid of MATLAB software 2017a version . The trans formation was performed on the training set , when the moments value were saved for future scaling of the test data .
  • ANN arti ficial neural network
  • ANN model optimi zation (based k- fold cross-validation) - Simple ANN architectures such as 1 -hidden layer with limited number of neurons , was used in order to reduce the chance for overfitting - the lesser number of neurons in use the lower network complexity .
  • the best architecture was chosen with the aid of a cross-validation test : the number of neurons in the hidden layer was varied to test the network performance on a validation set . The upper bound of the number of neuros was set such that it is smaller than the number of the model weights . Then the number of neurons with the best score ( in terms of the root mean square error between the known concentration and those who were estimated on the validation set) was chosen. The test was repeated with different initial conditions (e.g., different weight initializations) , because ANN models are significantly affected by their initial conditions; but in each individual test the parameters were fixed in order to make unbiased and robust decision.
  • initial conditions e.g., different weight initializations
  • Model training having determined the best architecture, it was now used for training the model across the entire training set.
  • the number of the training iterations was limited (early stopping) according to a specific error value that was set to stop the training procedure after reaching at least 99% of the target variance.
  • a trained network which minimizes the performance on the training data is created, ready for future testing.
  • test data pre-processing - based on the selected features in the feature selection procedure, the test features were loaded and standardized according to the training moments. For each feature, the training mean value was subtracted and the result divided it by the training standard deviation (this procedure is based on the fact that the two sets sampled from the same data population) , creating a scaled data set.
  • ANN predictability The trained model was used to test and evaluate the performance on unseen data set, i.e., on the test set which was preprocessed and was ready for use as the model input. Calculations were performed in MATLAB software 2017a version, using the ANN toolbox function and aid function coded for specific tasks .
  • the metrics for classification models were:
  • the invention relates to a method as described above for screening a patient for urologic cancer to determine, for a cancer patient or a subject suspected of having cancer, if the organ of cancer involvement is the urine bladder or prostate, wherein the chemometric model applied is an artificial neural network-based model that was trained with a training data set consisting of urine samples taken from bladder and prostate cancer patients, and optionally renal cancer, upper tract cancer patients and inflammation .
  • 1-50 e.g., 1-8) features are extracted for each electrode and from 1-50 (e.g., 1-20) nodes were applied in ANN.
  • the invention relates to a method as described above for screening a patient to determine if a patient has bladder cancer or inflammation, wherein the chemometric model applied is PLS-DA that was trained with a training data set consisting of urine samples taken from bladder cancer patients and patients having inflammation. At least one feature extracted for each electrode.
  • the method of the invention can be used for cancer monitoring.
  • monitoring is meant, for example, tracking the recurrence and/or progression of cancer, classi fication of tumor according to WHO (World Health Organi zation) or EAU (European Association of Urology) guidelines , and ef fectiveness of treatment .
  • WHO World Health Organi zation
  • EAU European Association of Urology
  • the invention provides a method of monitoring a patient concerning a cancer detectable in urine , comprising : obtaining a urine sample from the patient ; acquiring an electrochemical signal generated j ointly by redox molecules in the urine sample , wherein the signal is acquired with the aid of an array of surface-modi fied electrodes that is sensitive for antioxidant and oxidant , and optionally a bare electrode ; optionally preprocessing the electrochemical signal , to obtain processed data ; applying trained chemometric model ( s ) to the proces sed or raw data ; and determining recurrence and disease progression, tumor classi fication as explained above , and/or treatment response , after the chemometric model has classi fied the processed data according to its training data set .
  • Figure 1 shows the maj or components of the approach to urinary detection of BC or PC patients , namely, a urine sample that was taken from a patient and an array of electrodes to be inserted into the sample .
  • Figure 2 shows a linear relationship between the AA concentration and the absorbance at 600nm .
  • Figure 2B shows that polynomial relationship was observed between the log ( concentration) to the net optical density ( OD) .
  • Figure 3 shows the 3D printed cell cap, which was used for the measurements .
  • Figure 4 is a voltammogram showing the detectability of the redox reaction by the bare and surface- modi fied electrodes .
  • Figures 5A and 5B show current peak versus concentration plots based on the signals recorded by the bare electrode in ascorbic acid solutions with varying concentrations , and the calibration curve showing linear relationship .
  • Figures 6A- 6D show LOD and sensitivity in the form of bar diagrams .
  • Figure 7 is a bar diagram, showing partial selectivity for each one of the five types of electrodes used, in relation to ascorbic acid and hydrogen peroxide .
  • Figure 8 shows a cell cap with the six-electrode array design
  • Figures 9 and 10 show the voltammograms recorded by DPV of the urine samples .
  • Figure 11 shows a design of a microsensor .
  • Figure 12 shows detection device into which an electrochemical sensor is incorporated .
  • Figure 13A shows a design of an array of electrodes and Figure 13B is a photograph showing a plastic housing encasing the electrode array .
  • Figure 14 shows the 2-ways voltammograms recorded by DPV of the urine samples using the modi fied commercial screen-printed- electrode ( SPE ) with 8-working carbon electrodes of Figure 13A.
  • Platinum black deposition solution was prepared by mixing 0.5g of chloroplatinic acid and 25mg of lead acetate in 50 ml of DI water. The mixture was then stirred and 3.9 pL of concentrated hydrochloric acid (32%; 10.2 Molar concentration) was added to the solution. The prepared solution was covered with aluminum foil and stored at room temperature.
  • 10 ml of 1 mg/mL rGO electrodeposition solution was prepared by diluting 2.5 ml of graphene oxide 4 mg/mL solution, with NaCl 100 mM in 5.5 ml DDW.
  • the graphene oxide (GO) solution was prepared using a modified Hummers' method.
  • a 9:1 ratio of sulfuric acid and phosphoric acid (100 mL) was prepared and stirred for several minutes.
  • a graphite powder (7.5 g/L, 1 wt . eq.) was added to the mixture under stirring conditions.
  • Potassium permanganate 45 g/L, 6 wt . eq.) was slowly added to the solution and the mixture was stirred for 6 h at 30-35 °C until the color turned to dark green.
  • IM H2SO4 electrodeposition solution 200 ml of 0.1 mg/ml Molybdenum Disulfide 0.
  • IM H2SO4 electrodeposition solution was prepared by diluting 20ml 1.0 mg/ml Molybdenum Disulfide solution, with 0.98 ml H2SO4 in 179.02 ml DDW. The mixture was sonicated for 10 min.
  • IM H2SO4 electrodeposition solution 200 ml of 0.1 mg/ml Tungsten Disulfide 0.
  • IM H2SO4 electrodeposition solution was prepared by diluting 20ml 1.0 mg/ml Tungsten Disulfide solution, with 0.98 ml H2SO4 in 179.02 ml DDW. The mixture was sonicated for 10 min.
  • a chronopotentiometry technique was employed to electrodeposit chitosan from the solution of Preparation 1 onto gold electrodes over 300 s, at cathodic current density of 6 A/m 2 , using a two- electrode configuration (a platinum wire as a counter electrode, and the gold as a working electrode) .
  • the modified electrodes were rinsed in double-distilled water (milli-Q, 18 MQ) to remove chitosan that was not bound to the electrode.
  • a three- electrode cell configuration consisting of the gold electrode (working electrode; 'WE' ) , an externally applied commercial Pt wire (CHI115, CH Instruments; counter electrode; 'CE' ) , and a Tungsten needle (P/N H-20242, Quarter) coated with Ag/AgCl ink (011464, BAS Inc.; pseudo reference electrode; 'RE' ) .
  • the first design consisted of ten working electrodes divided equally into five sets as follows:
  • the second design consisted of six working electrodes divided equally into three sets as follows:
  • the geometrical arrangement of the electrodes is illustrated in the experimental setups that are shown in the next set of Examples.
  • the electrodes were inserted into the solution/sample in an electrochemical cell through the holes of a suitably perforated cell cap; the set of working electrodes and one reference electrode were arranged along the circumference of a circle encircling a centrically positioned counter electrode.
  • a commercial screen-printed-electrode (SPE) with 8 working carbon electrodes of 2.95mm diameter was used (Metrohm DropSens) .
  • the working electrodes were sharing a silver reference electrode, and a carbon counter electrode.
  • the SPE substrate material was ceramic. The geometrical arrangement of the electrodes is illustrated in Figure ISA.
  • the surface of the electrode was cleaned by cyclic voltammetry using 0.5M H2SO4 sulfuric acid.
  • the electrodes were further rinsed with double-distilled water.
  • the electrochemical activity of the electrodes was validated by cyclic voltammetry (CV) measurement in 5mM ferrocyanide/ ferricyanide solution. Then each electrode was rinsed with double distilled water (DDW) and coated with appropriate coating.
  • CV cyclic voltammetry
  • a chronopotentiometry technique was employed to electrodeposit platinum black from the solution of Preparation 3 onto carbon electrode over 5 mins, at cathodic current density of 4.8 mA/ cm 2 , using commercial platinum wire and Ag/AgCl reference electrodes (ASL, Japan) .
  • the modified electrodes were rinsed in doubledistilled water (milli-Q, 18 MQ) to remove residuals.
  • a commercial Ag/AgCl reference electrode (ALS, Japan) was used.
  • a commercial Ag/AgCl reference electrode (ALS, Japan) was used.
  • a commercial Ag/AgCl reference electrode (ALS, Japan) was used.
  • Carbon electrode was left untreated.
  • the carbon electrodes were rinsed in double-distilled water (milli-Q, 18 MQ) to remove residuals .
  • Tungsten Disulfide Type A-coated electrodes (Figure 13A, Working Electrode 6, Pin 7) :
  • a commercial Ag/AgCl reference electrode (ALS, Japan) was used.
  • Tungsten Disulfide Type B-coated electrodes (Figure 13A, Working Electrode 7, Pin 8) :
  • a commercial Ag/AgCl reference electrode (ALS, Japan) was used.
  • a chronopotentiometry technique was employed to electrodeposit chitosan+CNT from the solution of Preparation 2 onto carbon electrode over 5 mins, at cathodic current density of 0.595 mA/ cm 2 , using commercial platinum wire and Ag/AgCl reference electrodes (ASL, Japan) .
  • the modified electrodes were rinsed in doubledistilled water (milli-Q, 18 MQ) to remove residuals.
  • TAG _ assay based _ on _ the _ ABTS _ (2,2' -Azino-bis ( 3- ethylbenzothiazoline-6-sulfuric acid) test the first reagent is 0.4M acetate buffer solution (pH 5.8) that contains sodium acetate solution (470 ml) and acetic acid solution (30 ml) .
  • the acetate solution contains 16.4 g sodium acetate dissolved in 500 mL of ultrapure water.
  • the acetic acid solution contains 1.1484 ml of reagent-grade glacial acetic acid that was added to 48.8516 ml ultrapure water.
  • the second regent is ABTS radical in acetate buffer (30 mM, pH 3.6) .
  • the acetate buffer solution contains 37.5 mL sodium acetate solution that was mixed with 462 mL of the acetic acid solution.
  • the sodium acetate solution contains 1.23 g sodium acetate dissolved in 500 mL of ultrapure water.
  • the acetic acid solution contains 861.3 pL of reagent-grade glacial acetic acid was added to 499.1387 mL of ultrapure water.
  • 8.0833 pL of H2O2 was diluted in 25 ml acetate buffer (described above) .
  • 0.1372 g of ABTS was dissolved in the prepared solution.
  • the first reagent contains 150 pM xylenol orange, 140 mM NaCl, and 1.35 M glycerol.
  • a 250 ml solution of the reagent was prepared from 0.0285 g of xylenol orange, 2.045 g of NaCl, 225 mL of 25mM H2SO4 and 25 mL of glycerol.
  • the second reagent contains 5 mM Ferrous ammonium sulfate, and 10 mM o-dianisidine dihydrochloride.
  • H2O2 solutions Two hydrogen peroxide solutions were prepared at concentrations of 4 mM and 400pM. Then, each of these solutions was serially diluted in ultrapure water and PBS over the range of 0.125 mM up to 4mM and 12.5 pM up to 400 pM for the calibration curve performance of the spectrophotometric TOS assay and the electrochemical response validation.
  • the PBS phosphate buffer saline
  • the PBS was prepared by dissolving 1779.9 mg sodium phosphate dibasic, 244.96 mg sodium phosphate monobasic, 8.006 g sodium chloride and 201.28 mg potassium chloride in IL of deuterium-depleted water (DDW) , to obtain for 10 mmol/L solution at pH 7.4.
  • DDW deuterium-depleted water
  • TAG Determination of TAG: a of a sample and of reagent 1 were added to a 96-well plate and incubated for 2 minutes. Then, the absorbance was measured at 600nm. After that, of reagent 2 was added to the reaction. After 5 minutes incubation, the second measurement was taken. The difference between the first to second measurements was used to calculate TAG in all assays. The results were expressed in millimoles of ascorbic acid equivalents per liter .
  • the TOS method is based on a colored complex formed between the ferric ion and xylenol orange in an acidic medium.
  • TOS assay briefly, first, of sample and of reagent 1 were added to a 96-well plate and incubated for 2 minutes. Then, the absorbance was measured at 560nm followed by secondary measurement at 800nm . After that , of reagent 2 was added to the reaction . After 5 minutes incubation the third and fourth measurements were taken at the same wavelengths . The di f ference between the first to the second measurements and between the third to the fourth measurements were used to calculate TOS in all assays . The assays results were expressed in micromoles of hydrogen peroxide equivalents per liter .
  • Figure 2A shows that linear relationship was observed between the AA concentration and the absorbance at 600nm, as expected (the higher the AA concentration, the higher the absorbance at 600nm) .
  • Figure 2B shows that polynomial relationship was observed between the log ( concentration) to the net optical density ( OD) .
  • OD optical density
  • Part B electrochemical response validation of the ten-electrode array design
  • the cap is shown in Figure 3 .
  • the cap is perforated with twelve holes , which include a centrically located hole for positioning Pt counter electrode and eleven holes arranged in a ring fashion encircling the Pt counter electrode , to position the ten working electrodes ( their holes are labeled by numbers 1 to 10 ) and Ag/AgCl reference electrode ( its hole is labeled by the letter R) .
  • the electrodes inserted into the solution through the holes ( 1 mm in diameter ) were connected to a potentiostat and a computer ( Ivium potentiostat and IviumSoft software ) .
  • the experimental setup was used to characterize the electrochemical performance of the coated electrodes towards the benchmark (part Bl) and markers associated with TAG (ascorbic acid) and TOS (hydrogen peroxide) (part B2) .
  • Fj which is the non-selectivity factor in relation to analyte j, and is defined as: where Sj is the average response slope, as defined in equation (2) , and Sj is its standard deviation.
  • Sj is the average response slope, as defined in equation (2)
  • Sj is its standard deviation.
  • Partial selectivity is calculated by dividing the sensitivity of electrode i towards analyte j ( ascorbic acid) by the sensitivity of the same electrode towards the other analyte k (H2O2 ) , namely, by dividing the corresponding slopes of the calibration curves .
  • the results are shown graphically in Figure 7 , in the form of bar diagrams , and in tabular form, for each one of the five types of electrodes used, in relation to ascorbic acid and hydrogen peroxide (namely, a pair of bars is assigned to each electrode type , though in fact is the inverse of . It is seen that the platinum black-coated electrode is unique in that it demonstrates increased partial selectivity towards hydrogen peroxide compared to the other electrodes .
  • the partial selectivity values were then used to calculate the cross reactivity ( CR) over various electrode combinations I , each combination consisting of three electrode types from the group G of five electrode types :
  • the set of operative electrodes may be reduced in number, e . g . , three types instead of five , using the cross-reactivity data as a selection criterion .
  • the platinum black and bare electrodes were chosen using the CR criteria (see Table 4) , and the electrode coated with chitosan-CNT was chosen owing to its good sensitivity towards hydrogen peroxide.
  • Differential pulse voltammetry was performed in the urine samples across the potential range of -0.1V to +0.7V.
  • the electrochemical signal was recorded by using MultiPalmSens4 and the MultiTrace software.
  • Figures 9 and 10 show the voltammograms recorded by DPV of the urine samples, after the application of baseline correction and electrode fusion to the original signal.
  • the obtained signal pattern is consistent with the theory that the redox spices are steadily depleted during the oxidation.
  • the current is dictated by the delivery of additional redox species via diffusion from the bulk solution, as the diffusion layer continues to grow with the scan, which slows down mass transport to the electrode.
  • the diffusion rate from the bulk solution to the electrode surface decreases, resulting in a decreased current as the scan continues.
  • the voltammogram is under diffusion control, whereas at the beginning it was the electrode kinetics which controlled the response.
  • Figures 9 and 10 one can also observe a shift of the signal between different electrodes and different cancer patients and that most of the signal variability is at the oxidation peaks.
  • At the chitosan-CNT electrode another peak was observed at 0.27 [V] .
  • the DPV generated signal was preprocessed with baseline correction method asymmetric least squares, electrode fusion, and data normalization .
  • Baseline correction baseline correction with asymmetric least square was performed, as described, for example, by PHC Eilers HB . Baseline correction with asymmetric least squares smoothing. Leiden Univ Med Cent Rep. 2005; 1 (1) :5 and Baek S-J, Park A, Ahn Y-J, Choo J. Baseline correction using asymmetrically reweighted penalized least squares smoothing. Analyst. 2015; 140 ( 1 ) : 250-257. doi : 10.1039/c4an01061b].
  • Electrode fusion this step involves the following treatment.
  • x is the estimated original signal, given by: Then, the mean estimated signal is equal to x as given by equation
  • ANN emerged as the best model for differentiating BC patients or PC patients from non-BC or non-PC patients.
  • the characteristics and performance of the ANN model from the grid search are tabulated below in Table 5A-5B (BC) and 5C-5D (PC) : Table 5A: BC Train (90%)
  • the goal of the study was to differentiate between the redox fingerprints of BC patients and healthy volunteers using a commercial screen-printed electrode (SPE) with 8 surface modified carbon electrodes of 2.95mm diameter.
  • the working electrodes were sharing a silver reference electrode, and a carbon counter electrode .
  • a total of fifty-nine (59) fresh urine samples (2 ml in size) were collected from twenty-five (25) bladder cancer patients.
  • the group consisted of eighteen (18) men and seven (7) women, with age between 49 to 86 years old.
  • twenty-five (25) fresh urine samples (2 ml in size) were collected from thirteen (13) healthy volunteers.
  • a drop of 2 ml fresh urine was placed on the modified commercial SPE, as shown in Figure 13B.
  • 2-ways differential pulse voltammetry was performed in the urine samples across the potential range of -0.1V to +0.7V (Oxidation) , and across the potential range of +0.7V to -0.1V (Reduction) with voltage step of 5mV, pulse mode of 50mV, pulse time of O.lsec, and scan rate of 0.02 V/sec.
  • the electrochemical signal was recorded using Palmsens Emstat Pico MUX16 board.
  • Figure 14 shows a voltammogram recorded by DPV of the urine samples both for oxidative and reduction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Business, Economics & Management (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Business, Economics & Management (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de criblage et/ou de surveillance d'un patient pour un cancer qui est détectable dans l'urine, comprenant : l'obtention d'un échantillon d'urine provenant du patient ; l'acquisition d'un signal électrochimique généré conjointement par les molécules redox dans l'échantillon d'urine, le signal étant acquis à l'aide d'un réseau comprenant des électrodes modifiées en surface qui sont sensibles à l'antioxydant et à l'oxydant, le réseau comprenant éventuellement en outre une ou plusieurs électrodes nues ; le prétraitement éventuel du signal électrochimique, pour obtenir des données traitées ; l'application d'un ou de plusieurs modèles chimiométriques entraînés aux données fournies ou brutes ; et la détermination de la présence de cancer et/ou de caractéristiques liées au cancer pouvant être surveillées, après que le modèle chimiométrique a classé les données traitées selon son ensemble de données d'apprentissage.
PCT/IL2023/051060 2022-10-03 2023-10-03 Procédé électrochimique de détection du cancer Ceased WO2024075123A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23874441.1A EP4599240A1 (fr) 2022-10-03 2023-10-03 Procédé électrochimique de détection du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263412817P 2022-10-03 2022-10-03
US63/412,817 2022-10-03

Publications (1)

Publication Number Publication Date
WO2024075123A1 true WO2024075123A1 (fr) 2024-04-11

Family

ID=90607679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2023/051060 Ceased WO2024075123A1 (fr) 2022-10-03 2023-10-03 Procédé électrochimique de détection du cancer

Country Status (2)

Country Link
EP (1) EP4599240A1 (fr)
WO (1) WO2024075123A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA65530A1 (fr) * 2024-04-19 2025-10-31 Université Sultan Moulay Slimane Capteur Electrochimique pour la caractérisation et la différenciation des tissus cancéreux.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022157753A1 (fr) * 2021-01-24 2022-07-28 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Analyse électrochimique de molécules redox-actives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022157753A1 (fr) * 2021-01-24 2022-07-28 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Analyse électrochimique de molécules redox-actives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LLUÍS PASCUAL: "Detection of prostate cancer using a voltammetric electronic tongue", ANALYST, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 141, no. 15, 1 January 2016 (2016-01-01), UK , pages 4562 - 4567, XP093156448, ISSN: 0003-2654, DOI: 10.1039/C6AN01044J *
SHUQING GU: "A droplet-based microfluidic electrochemical sensor using platinum-black microelectrode and its application in high sensitive glucose sensing", BIOSENSORS AND BIOELECTRONICS, ELSEVIER SCIENCE LTD, UK, AMSTERDAM , NL, vol. 55, 1 May 2014 (2014-05-01), Amsterdam , NL , pages 106 - 112, XP093156451, ISSN: 0956-5663, DOI: 10.1016/j.bios.2013.12.002 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA65530A1 (fr) * 2024-04-19 2025-10-31 Université Sultan Moulay Slimane Capteur Electrochimique pour la caractérisation et la différenciation des tissus cancéreux.

Also Published As

Publication number Publication date
EP4599240A1 (fr) 2025-08-13

Similar Documents

Publication Publication Date Title
US20200138344A1 (en) Electrochemical detection device and method
Wu et al. Sensitive and selective electrochemical sensor for serotonin detection based on ferrocene-gold nanoparticles decorated multiwall carbon nanotubes
Tertis et al. Impedimetric aptasensor for the label-free and selective detection of Interleukin-6 for colorectal cancer screening
Liu et al. An AgNP-deposited commercial electrochemistry test strip as a platform for urea detection
Ghanbari et al. Simultaneous electrochemical detection of uric acid and xanthine based on electrodeposited B, N co-doped reduced graphene oxide, gold nanoparticles and electropolymerized poly (L-cysteine) gradually modified electrode platform
CN102753965A (zh) 检测分析物
Xiao et al. Non-enzymatic lactic acid sensor based on AuPtNPs functionalized MoS2 nanosheet as electrode modified materials
Income et al. Disposable Nonenzymatic Uric Acid and Creatinine Sensors Using μPAD Coupled with Screen‐Printed Reduced Graphene Oxide‐Gold Nanocomposites
US20240369512A1 (en) Electrochemical sensor and determination of hydroxyurea
WO2021207842A1 (fr) Nanozymes avec agents de coiffage de piégeage de radicaux et leurs procédés de détection
Aydın et al. A Simple and Low‐Cost Electrochemical Immunosensor for Ultrasensitive Determination of Calreticulin Biomarker in Human Serum
WO2024075123A1 (fr) Procédé électrochimique de détection du cancer
Zhu et al. Highly sensitive electrochemical immunosensor based on methylene blue-reduced graphene oxide nanocomposites as signal probes for IL-6 detection in gingival crevicular fluid samples
Gautam et al. Real-time detection of plasma ferritin by electrochemical biosensor developed for biomedical analysis
Chen et al. Rapid and Ultrasensitive Electrochemical Detection of TP53 Gene Mutation in Blood: Hybridization with a DNA/Gold‐Coated Magnetic Nanoparticle Network
Saputra et al. Fundamentals and research progression on electrochemical sensing of colorectal cancer
Chen et al. Multi-enzyme mimic nanozyme with enhanced catalysis for methylene blue probe promotes the one-step detection of tau protein
Takita et al. Ultrasensitive prostate cancer marker PCA3 detection with impedimetric biosensor based on specific label-free aptamers
Djebbi et al. NZVI© Au magnetic nanocomposite‐based electrochemical magnetoimmunosensing for ultrasensitive detection of troponin‐T cardiac biomarker
Shi et al. Development of a dual-channel electrochemical aptasensor for simultaneous detection of CRP and IL-6 in sepsis diagnosis
EP4599250A1 (fr) Procédé électrochimique de test de stress oxydatif
US20240110885A1 (en) Electrochemical analysis of redox-active molecules
US20230112391A1 (en) Electrochemical Method for Detecting Clozapine
WO2025215645A1 (fr) Procédé électrochimique de détection de maladies
Zhang et al. An emerging machine learning-optimized MIP-ECL platform for ultrasensitive and selective detection of 5-hydroxytryptamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23874441

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2023874441

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2023874441

Country of ref document: EP

Effective date: 20250506

WWP Wipo information: published in national office

Ref document number: 2023874441

Country of ref document: EP